Agios Pharmaceuticals’ mitapivat shows significant promise in Phase 3 ENERGIZE study
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a pioneer in cellular metabolism and pyruvate kinase (PK) activation therapies, unveiled detailed results from the Phase 3 ENERGIZE study of mitapivat for non-transfusion-dependent (NTD) alpha- or beta-thalassemia. The findings, presented at the European Hematology Association 2024 (EHA2024) Hybrid Congress in Madrid, Spain, demonstrated significant improvements in hemoglobin levels and […]
